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There is a growing body of evidence supporting an increased
risk of cardiovascular (CV) mortality in patients with
rheumatoid arthritis (RA). This is the result of complex
mechanisms leading to accelerated atherosclerosis [1]. In
this regard, besides classic CV risk factors [2], chronic
inflammation [3] and a genetic component [3, 4] have been
proposed to influence the development of atherosclerosis in
RA.
This special issue encompasses diﬀerent aspects of the
CV disease associated to RA. With respect to this, the link
between atherosclerosis and RA was discussed. Surrogate
markers of atherosclerosis have been found to be useful
in predicting the presence of atherosclerosis disease in
subclinical stages in adults with RA [5, 6]. Data shown in
this special issue also confirmed that children with juvenile
idiopathic arthritis may have higher carotid intima-media
wall thickness index values than controls. These observations
emphasize the need for increased awareness of the risk of
atherosclerosis in children with juvenile idiopathic arthritis.
An exhaustive literature review on the genetic influence
in the development of CV disease in patients with RA was
also included. With respect to this, it is important to keep
in mind that besides gene polymorphisms located within the
MHC region [3, 4], variations of genes located outside this
region, such asCCR5,MTHF [7, 8], are of potential relevance
in the increased risk of CV disease associated to RA.
Adipokines are molecules not only implicated in the
development of metabolic syndrome but also in inflamma-
tory mechanisms that may play a role in the pathogenesis
of diﬀerent autoimmune diseases [9, 10]. A timely review
on the implication of adipokines in the development of the
atherosclerotic disease not only focusing on RA but also
discussing the link between these molecules and the presence
of atherosclerosis in other chronic inflammatory rheumatic
diseases was included in the special issue.
The mechanisms associated with endothelial dysfunc-
tion, an early step in the atherogenesis process, in patients
with RA are far from being completely understood. In
this special issue an assessment of the potential role of
asymmetric dimethylarginine and apelin as biomarkers to
detect early data of endothelial dysfunction in patients with
RA was included.
Anti-TNF-α drugs constitute the mainstay of therapy in
RA patients with severe disease that is refractory to conven-
tional disease modifying antirheumatic drugs. One of the
articles included in the special issue confirmed the previously
reported short-term beneficial eﬀect of the fully human-anti-
TNF-α monoclonal antibody adalimumab on endothelial
function [11]. In addition, new data showing persistent
improvement of endothelial function in adalimumab-treated
RA patients without progression of the carotid intima-media
thickness are reported. This is of potential relevance as
the use of anti-TNF-α therapy has been associated with
a decrease of mortality in RA patients, mainly due to a
reduction in the incidence of CV events [12].
In line with the above, Popa et al. had previously
assessed the eﬀects of the anti-TNF-α therapy on the HDL
antiatherogenic function. They observed that infliximab,
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a chimeric anti-TNF-α monoclonal IgG1 antibody was able
to improve HDL antioxidative capacity. This eﬀect was
sustained 6 months after anti-TNF-α therapy had been
initiated [13]. In this special issue the same group conducted
an extensive review on the eﬀect that diﬀerent biologic
therapies exert on the atherogenic index andHDL cholesterol
in patients with RA.
Taken together, these studies confirm the presence of
complex mechanisms that influence the development of
atherosclerosis in RA. Nevertheless, further studies are
needed to shed light on the problem of augmented risk of
CV disease in patients with RA.
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